Characteristics and Impact of Drug Detailing for Gabapentin

DSpace/Manakin Repository

Characteristics and Impact of Drug Detailing for Gabapentin

Citable link to this page

. . . . . .

Title: Characteristics and Impact of Drug Detailing for Gabapentin
Author: Steinman, Michael A; Chren, Mary-Margaret; Landefeld, C. Seth; Bero, Lisa A; Harper, Gordon P.

Note: Order does not necessarily reflect citation order of authors.

Citation: Steinman, Michael A., G. Michael Harper, Mary-Margaret Chren, C. Seth Landefeld, and Lisa A. Bero. 2007. Characteristics and impact of drug detailing for gabapentin. PLoS Medicine 4(4): e134.
Full Text & Related Files:
Abstract: Background: Sales visits by pharmaceutical representatives (“drug detailing”) are common, but little is known about the content of these visits or about the impact of visit characteristics on prescribing behavior. In this study, we evaluated the content and impact of detail visits for gabapentin by analyzing market research forms completed by physicians after receiving a detail visit for this drug. Methods and Findings: Market research forms that describe detail visits for gabapentin became available through litigation that alleged that gabapentin was promoted for “off-label” uses. Forms were available for 97 physicians reporting on 116 detail visits between 1995 and 1999. Three-quarters of recorded visits (91/116) occurred in 1996. Two-thirds of visits (72/107) were 5 minutes or less in duration, 65% (73/113) were rated of high informational value, and 39% (42/107) were accompanied by the delivery or promise of samples. During the period of this study, gabapentin was approved by the US Food and Drug Administration only for the adjunctive treatment of partial seizures, but in 38% of visits (44/115) the “main message” of the visit involved at least one off-label use. After receiving the detail visit, 46% (50/108) of physicians reported the intention to increase their prescribing or recommending of gabapentin in the future. In multivariable analysis, intent to increase future use or recommendation of gabapentin was associated with receiving the detail in a small group (versus one-on-one) setting and with low or absent baseline use of the drug, but not with other factors such as visit duration, discussion of “on-label” versus “off-label” content, and the perceived informational value of the presentation. Conclusions: Detail visits for gabapentin were of high perceived informational value and often involved messages about unapproved uses. Despite their short duration, detail visits were frequently followed by physician intentions to increase their future recommending or prescribing of the drug.
Published Version: doi:10.1371/journal.pmed.0040134
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855692/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4875895

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters